Evidence for the progression through S-phase in the ectopic cell
















































Alzheimer disease (AD) is a progressive and fatal 
neurodegenerative disease that is clinically characterized 
by  dementia  and  neurobehavioral  deterioration  [1-4]. 
While the hallmark features of amyloid plaques, neuro- 
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fibrillary tangles (NFTs), and neuronal loss are well 
established, the cause(s) of the disease remain elusive. 
Nonetheless, one mechanism that is gaining increased 
prominence is the ectopic re-entry of neurons into the 
cell cycle [5], which accumulate cyclins, CDKs, and 
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re-entry mediates AD-type changes [23] and is linked 
with cell death [24-27],  a number of unanswered 
questions remain [28]. For example, it is still unclear 
whether the presence of various cell cycle markers 
represent a bona fide cell cycle or are they, instead, 
consequential to other pathological processes (e.g., 
apoptosis). Also, if representative of cell cycle, it is 
unclear why neurons do not progress and enter 
cytokinesis. One fitting hypothesis is that some cells 
undergo hypermitogenic cell cycle arrest, as an 
alternative to apoptosis, which would result in cell 
senescence and survival [29]. 
 
The minichromosome maintenance proteins are a 
eukaryotic family of six distinct protein subtypes 
(Mcm2-7) that are necessary for DNA replication 
initiation and progression in the cell cycle [30]. During 
the G1-phase of the cell cycle, the hexameric Mcm2-7 
complex assembles at origins of replication on nuclear 
DNA [31]. Once in S-phase, the complex is phospho-
rylated by the Cdc7/Dbf4 kinase and the B-type CDKs, 
and acting as the DNA helicase initiates DNA 
replication at origins and allows progression of the 
replication forks [32-37]. The assembly of the Mcm 
complex is tightly regulated, can occur only in G1 when 
the activity of CDKs and Cdc7 is low, and is actively 
prevented once cells enter S-phase till exit of mitosis 
when the activity of these kinases is high [38], such that 
replication only occurs once per cell cycle. Expression 
of Mcm proteins is restricted to actively cycling cells 
and is a good proliferation marker [39]. While in 
budding yeast Mcm2-7 proteins shuttle in and out of the 
nucleus, human Mcms are generally detected in the 
nuclear compartment [40, 41]. Phosphorylation can 
occur at multiple sites, however phosphorylation of 
Mcm2 in two adjacent sites Ser40 and Ser41, carried 
out in succession by CDKs and Cdc7, strictly correlates 
with cells undergoing or having terminated DNA 
synthesis [42]. As such, antisera specific for pSer40/41 
Mcm2 phosphorylation provides an excellent marker for 
the detection of cells in a late stage of the cell cycle.  
 
I n  t h i s  s t u d y ,  w e  c o m p a r e d  S e r 4 0 / 4 1  M c m 2  
phosphorylation in AD and aged-matched control brain. 
In AD, phosphorylated Mcm2 localized to the cyto-
plasm of neurons, and strikingly with the characteristic 
NFT. These findings further support the notion that 
neurons in AD re-enter the cell cycle, pass through S-
phase by activating the only two essential S-phase 
promoting kinases, and provide evidence for aberrant 





Phosphorylated Mcm2 protein at a CDK- and Cdc7- 
dependent site is localized to the cytoplasm of AD 
neurons and targets neurofibrillary tangles and 
amyloid plaques 
 
The presence of pSer40/41 Mcm2 (pMcm2) protein was 
detected using the immunocytochemistry methods 
discussed in the corresponding section. All of the AD 
cases examined demonstrated significant accumulation 
of pMcm2 in NFTs, dystrophic neurites, and neuropil 
threads (Figure 1B). In most cases, glial nuclei were 
often stained, and in a small number of cases, some 
pyramidal cell nuclei within the CA3 region showed 
significant pMcm2 reactivity (Figure 1D, arrows). In 
similar areas in most control cases, no staining was seen 
(Figure 1A), in a small number of aged control cases, 
pyramidal neuron nuclei showed high pMcm2 protein 
levels (Figure 1C). In some of the aged controls, a small 
number of pathological structures (NFT, neuropil 


































demonstrate  significant  localization  of  pMcm2  protein  in  NFT,
dystrophic neurites, and neuropil threads (B).  In another AD case,
in  the  CA3  region,  in  addition  to  pathological  structures,  a  few
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methacarn fixation, contained many immunoreactive 
NFT throughout the hippocampus. Additionally, the 
binding of the anti-pMcm2 antibody to NFT within AD 
brains was striking and showed some co-localization 
with phosphorylated tau on adjacent sections of AD 
tissue In particular, many of the same NFT and senile 
plaques demonstrated co-localization of tau with 
pMcm2 in all AD cases (Figure 2). In Figure 3, the 
specificity of the antibody to pMcm2 protein was 
confirmed by absorbing antibodies to pMcm2 with 












































expected, the phosphorylated peptide completely 
absorbed the antibody producing no visible staining on 
the section (Figure 3C) whereas the peptide lacking 
phosphorylation failed to absorb the antibody (Figure 
3B) and produced staining similar to that of the 
unabsorbed sample (Figure 3A). Further confirmation 
of the specificity was obtained by treating some sections 
with alkaline phosphatase to remove phosphate groups. 
Figure 4 shows that nearly all of the reactivity of the 
pMcm2 antisera is abolished following dephosphoryla-
tion on adjacent sections with (Figure 4B) and without 







and  plaques  recognized  by  pMcm2  (C)  and  AT8  (D).  *  denotes
landmark vessel. Scale bars= 50 μm (A,B), 100 μm (C,D). 








absorbed  with  non‐phosphorylated  Mcm  peptide
demonstrates similar staining. (C) Adjacent section
treated  with  pMcm2  antibody  absorbed  with
phosphorylated  Mcm2  peptide  demonstrates
complete absorption. * denotes landmark vessel. 
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In AD, multiple lines of evidence suggest that neurons 
vulnerable to degeneration emerge from the post-
mitotic, quiescent state and are phenotypically 
suggestive of cells that are cycling, rather than being in 
the normal, terminally differentiated, non-dividing state 
[43]. Such cell cycle re-entry has not only been linked 
to cell death [44], but has also been implicated in the 
hallmark pathologies of the disease, namely tau 
phosphorylation and amyloid-β (Aβ) [23]. Nonetheless, 
despite the identification of a variety of cell cycle 
proteins in AD, there remains controversy over whether 
these are truly indicative of a bona fide reaction of the 
cell cycle or, instead, reflect the pleotrophic actions of 
these protein markers [28]. Indeed, proteins previously 
detected in AD such as Ki67, PCNA, cdc2, cdk4, 
BRCA1 and pRb [9, 44-49], although noted regulators 
of the mitotic process, are also involved in neuronal 
processes unrelated to the cell cycle such as DNA repair 
[50], apoptosis [51], and oxidative stress [52]. Here, 
however, the detection of a key component of the DNA 
replication machinery Mcm2, phosphorylated in the 
Cdk and Cdc7 dependent site Ser40/41 in AD neuronal 
cytoplasm and NFT not only provides additional 
support for the cell cycle hypothesis of AD [10], but 
supports an authentic re-entrant phenotype associated 
with DNA replication [53]. Mcm2 is in fact not 
expressed in non-proliferating tissues, as shown in 
neurons in age-matched control brain, but it 
accumulates in G1 cells re-entering the cell cycle. Dual 
phosphorylation of Mcm2 at serine 40 and serine 41, 
then requires the activity of two kinases whose activity 
is upregulated in S-phase by the periodic expression of 
regulatory subunits, Cyclin and Dbf4 [54]. 
 
Very intriguingly, pMcm2 in AD neurons, unlike in 
most cancer cell lines [42], appears to accumulate 
mostly in the cytoplasm suggesting further degree of 
deregulation of the MCM complex in disease tissues 
that may explain the inability of neurons to progress 
through cytokinesis.  
 
The ectopic re-entry of neurons into the cell cycle likely 
plays an important role mediating other aspects of AD 
pathology. Specifically, the microtubule associated 
protein tau, in cases of AD, exists in a highly 
phosphorylated form and composes the NFTs that 
burden the diseased brain, and this increased 
phosphorylation of tau destabilizes microtubular 
dynamics and results in neuronal dysfunction [55, 56]. 
Interestingly, while cells are mitotically active, the cell 
cycle regulator proteins CDKs initiate a similar 
phosphorylation of tau that precedes the appearance of 
the NFTs [8] and suggests a possible cause-effect 
relationship [23]. Similarly  the major protein 
component of senile plaques is a 4.2 kDa polypeptide 
termed Aβ, which is derived from a larger precursor 
(APP) encoded on chromosome 21. Attesting to the 
importance of this protein, mutations in the APP gene 
are linked to the inevitable onset of familial AD [57]. 
Given the probable role of mitotic re-entry in AD, it is 
notable that APP is upregulated secondary to mitogenic 
stimulation [58] and that APP metabolism is regulated 
by cell cycle-dependent changes [59]. Interestingly, Aβ 
itself is mitogenic in vitro [60, 61] and therefore may 
play a direct role in the induction and/or propagation of 
cell cycle-mediated events in AD. Additionally, Aβ-
mediated cell death, at least in vitro, is dependent on the 
presence of various cell cycle-related elements [62]. 
Most importantly, the ectopic re-entry of neurons into 
the cell cycle was recently shown to lead to cell death, 
gliosis, and cognitive deficits—all cardinal features of 
AD [24].  
 
In conclusion, our results provide further support for the 
role of cell cycle re-entry in the initiation and 
progression and AD. As such, cell cycle inhibitors 




Tissue. Autopsy tissue samples were obtained using a 
protocol approved by the Institutional Review Board at 
University Hospitals of Cleveland. Hippocampal or 
cortical tissue samples were obtained post mortem from 
patients (n = 10, ages 63-91 years, mean = 81.8 years) 
with clinically and histopathologically confirmed AD, 
as well as from aged-matched controls (n = 8, ages 56-
86 years, mean = 70.2 years) with similar post mortem 
intervals (AD: 2-31 h, mean = 14.5 h; controls: 5-27 h, 
mean = 15.6 h). All cases were categorized based on 
clinical and pathological criteria established by CERAD 
and NIA consensus panel [64]. From the clinical reports 
available to us, we found no obvious differences in 
agonal status or other potential confounders between the 
groups. Tissue was fixed in methacarn (methanol: 
chloroform: acetic acid; 6: 3: 1 v/v/v) at 4°C overnight 
or in routine formalin. Following fixation, tissue was 
dehydrated through ascending ethanol, embedded in 
paraffin, and 6-μm sections were cut. 
 
Immunohistochemistry.  Tissue sections were deparaf-
finized in xylene, hydrated through descending ethanol, 
and endogenous peroxidase activity was quenched by 
30 minute incubation in 3% hydrogen peroxide in 
methanol. Non-specific binding sites were blocked with 
30 minute incubation in 10% normal goat serum. 
Sections of both AD and control were immunostained 
with rabbit polyclonal antibody to Mcm2 phosphor-
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monoclonal antibody to tau (AT8 1:1000) recognizing 
phosphorylated tau (Ser202/Thr205) (Pierce, Rockford, 
IL) to identify the location of neuronal pathological 
structures. Absorption experiments were performed to 
verify the binding of the Mcm2 Ser40/41 antibody to 
the appropriate phosphorylated peptide. The primary 
antibody was incubated in 0.2mg/ml peptide containing 
0 or 2 phosphates for 16 hours at 4ºC prior to 
immunostaining. All sections were immunostained 
using the peroxidase-antiperoxidase with 3-3'-
diaminobenzidine as co-substrate as previously 
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